Crispr Therapeutics (NASDAQ:CRSP) had its target price increased by Canaccord Genuity from $72.00 to $80.00 in a report released on Wednesday, November 20th, The Fly reports. Canaccord Genuity currently has a positive rating on the stock.
A number of other equities analysts have also weighed in on the company. Oppenheimer raised Crispr Therapeutics from a market perform rating to an outperform rating and set a $65.00 price objective on the stock in a research note on Tuesday, November 12th. Piper Jaffray Companies upped their price target on Crispr Therapeutics from $100.00 to $107.00 and gave the company a buy rating in a research note on Tuesday, November 19th. Roth Capital upped their price target on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Goldman Sachs Group boosted their price objective on Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a report on Tuesday, November 19th. Finally, Chardan Capital reiterated a buy rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a report on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $69.54.
CRSP stock traded up $3.54 during trading on Wednesday, hitting $71.65. 1,013,423 shares of the company traded hands, compared to its average volume of 1,505,783. The company has a market cap of $3.80 billion, a PE ratio of -20.83 and a beta of 3.15. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $74.00. The stock’s 50-day simple moving average is $49.98 and its 200 day simple moving average is $46.23. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Research analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. Insiders own 21.40% of the company’s stock.
Several hedge funds have recently modified their holdings of CRSP. Xact Kapitalforvaltning AB purchased a new position in Crispr Therapeutics in the 2nd quarter valued at approximately $207,000. Commonwealth Equity Services LLC increased its position in Crispr Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after buying an additional 986 shares in the last quarter. Buckley Wealth Management LLC purchased a new position in Crispr Therapeutics during the second quarter worth $236,000. Carnegie Capital Asset Management LLC purchased a new position in Crispr Therapeutics during the second quarter worth $1,064,000. Finally, Moody Aldrich Partners LLC acquired a new stake in shares of Crispr Therapeutics during the second quarter worth $1,838,000. 49.81% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What are retained earnings?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.